INDUSTRIAL IMPACT, MEDICAL
Twist Bioscience | March 10, 2023
On March 9, 2023, Twist Bioscience Corporation, a leading firm providing high-quality synthetic DNA through its silicon platform, announced the launch of integrated antibody discovery services. This premium offering combines the company's synthetic libraries and AI machine learning with an in vivo immunization approach acquired through its acquisition of Abveris, also known as Twist Boston. This service provides customers with optimized, development-ready antibody candidates.
The combined team, now called Twist Biopharma Solutions, is led by Tracey Mullen, MBA, the senior vice president of biopharma for Twist Bioscience. This newly formed entity leverages years of industry expertise, scientific excellence, and proprietary technology to discover the best antibody candidate for therapeutic targets of interest.
Twist Biopharma Solutions offers an end-to-end workflow for centralized antibody discovery and optimization, including target validation, hit generation, lead selection, lead optimization, and lead characterization. Twist, supported by high-throughput DNA synthesis and IgG antibody production, constructs extensive and particular synthetic antibody libraries with discovery starting with either in vivo or in vitro diversity.
The newly integrated in vivo discovery approach from Abveris of single B cell screening and hybridoma discovery enables parallel paths where multiple technology methods can be leveraged to build a panel of highly diverse antibody leads with broad epitope coverage. In addition, this multi-pronged approach can increase the likelihood of discovering highly specific, high-affinity functional antibodies by sampling synthetic and natural diversity.
The South San Francisco and Boston biopharma teams were combined to create Twist Biopharma Solutions, led by Tracey Mullen. Aaron Sato, Ph.D., remains integrally involved in Twist Biopharma Solutions and, as a chief scientific officer of Twist Bioscience, extends his expertise across the organization. Tracey Mullen joined Twist Bioscience in November 2021 through the acquisition of Abveris. In April 2022, she took on the position of senior vice president of operations, driving the completion of the Factory of the Future in Wilsonville, Oregon, which began shipping products in January 2023. Before joining Twist, she served as CEO of Abveris and worked on the antibody discovery team at Biogen.
About Twist Bioscience
Twist Bioscience is a leading biotechnology company specializing in synthetic biology and genomics. It has developed a proprietary DNA synthesis platform that enables the production of custom-designed DNA strands faster, more accurately, and at a lower cost than traditional methods. In addition, Twist collaborates with partners across industries to develop customized DNA sequences for specific applications and offers a range of other products and services, such as oligonucleotides, synthetic genes, and custom panels for next-generation sequencing. The company has also developed a library of over 100 billion synthetic antibodies, which can be used for diagnostic and therapeutic applications.
Read More
MEDTECH, INDUSTRIAL IMPACT
SOPHiA GENETICS | March 01, 2023
On February 28, 2023, SOPHiA GENETICS, a leading cloud-native software solutions provider in the healthcare space, announced that Synergy Oncology, a part of Synergy Laboratories based in Mobile, Alabama, will utilize SOPHiA DDM™ to develop a new cancer profiling solution. Synergy Oncology is a specialist in innovative platforms that improve patient care.
The use of SOPHiA DDM™ for Hereditary Cancers Solution in Synergy Oncology's state-of-the-art laboratory technologies will lead to the launch of Totality, a comprehensive end-to-end solution for tumor profiling that will assist clinical studies, cancer research and patient care.
Next-generation sequencing (NGS) is commonly used to detect biomarkers for hereditary cancers, but the resulting datasets are vast and complex, requiring sophisticated analysis. The SOPHiA DDM™ for Hereditary Cancers Solution leverages machine learning and Artificial Intelligence (AI) with patented technologies to evaluate raw NGS data, simplifying interpretation and expediting reporting. As Synergy Laboratories seeks to expand into other oncology offerings, the SOPHiA DDM™ platform could serve as a one-stop solution.
Synergy's new product, Totality, examines genes from solid tumor tissue and, by using SOPHiA DDM™ for Hereditary Cancers, provides physicians with a consolidated report that matches detected molecular alterations with clinical trials and FDA-approved therapies. By combining SOPHiA DDM™ for Hereditary Cancers with Synergy Oncology's technology, experts will be able to analyze and interpret findings from NGS data confidently, transforming high-quality data into valuable insights for researchers and care providers.
Synergy Oncology provides the most comprehensive NGS kit of its kind, including hereditary testing, liquid biopsy testing, and myeloid malignancies. The combination of Synergy Oncology and SOPHiA GENETICS technology will expand Synergy's oncology portfolio while helping to further the U.S. oncology market.
About SOPHiA GENETICS
SOPHiA GENETICS is a leading cloud-native software solutions provider in the healthcare space. It aims to establish data-driven medicine as the standard of care for life sciences research. The company combines expertise in life sciences, data computing and medical disciplines to bring data analytics solutions to market. SOPHiA GENETICS achieve its mission through the global adoption of SOPHiA AI, which uses pattern recognition, statistical inference and machine learning to provide equal benefits to all users. SOPHiA AI also encourages expert knowledge sharing for a sustainable impact on future patients. The company believes digital technologies are the key to unlocking the era of Data-Driven Medicine, where secure data pooling and knowledge sharing will be precious for patients. The company also focuses on combining the first two pillars of Data-Driven Medicine, Radiomics and Genomics, to ensure that the data used to help patients today will also benefit tomorrow's patients.
Read More
INDUSTRIAL IMPACT, MEDICAL
Synthego | March 17, 2023
Synthego Corp., a leading genome engineering solutions provider, announced today the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services. The ecosystem brings together high-value partners including Arctoris, BrainXell, Curia, PhenoVista, and Pluristyx to offer a coordinated solution for CRISPR-driven drug discovery.
The CRISPR Discovery Partner ecosystem creates an integrated workflow starting with Synthego's CRISPR Engineered Cells through functional readouts, providing researchers with a faster, more efficient, and more reliable way to move their discoveries forward. Researchers can access the full range of genome engineering services through Synthego, as well as downstream services including small molecule screening, cell-based assays, high content imaging, iPSC differentiation, and multi-omics through partners. The result is a streamlined drug discovery process that can help accelerate the development of life-saving treatments.
Synthego's CRISPR Discovery Partners include
Arctoris, a tech-enabled drug discovery service company, combines wet lab automation and machine learning with a world-class team of experienced drug discovery researchers to enable the accelerated development of small molecule, biologics, and cell therapy assets.
BrainXell provides differentiation services to generate high-purity, iPSC-derived human neurons, astrocytes, and microglia for research use with a focus on drug discovery. BrainXell also offers fibroblast reprogramming and select downstream assay services.
Curia, a global contract research, development and manufacturing organization (CDMO), offers products and services from discovery through manufacturing to help customers transform R&D results into real-world impact.
PhenoVista, a San Diego-based CRO, specializes in modern, human, cell-based in vitro assay development and analysis. Internationally recognized for developing and implementing both fully bespoke projects and pre-validated Ready-2-Go assay services, this award-winning research partner leverages high-content imaging to enable life scientists to accelerate their discovery of novel therapeutics and improve global health.
Pluristyx offers expertise and tools to support and accelerate the development and commercialization of revolutionary therapeutics to treat serious human diseases by providing unique products, consulting, and contract services, including cell line expansion and banking.
About Synthego
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms and products for science at scale. With its foundations in engineering disciplines, the company's platform technologies vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance basic research, target validation, and clinical trials. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation enabling the next generation of medicines by delivering genome editing at an unprecedented scale.
Read More